Christine Lovly

From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.
April 11, 2019

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

By Tom Wilemon
February 28, 2019

Investigators map genomic landscape of very rare cancer

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

By Tom Wilemon
June 14, 2018

Lung cancer patients and advocates visit VUMC research labs

A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.

By VUMC News and Communications
March 8, 2018

Lovly earns scholarship grant for lung cancer research

Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer.

By VUMC News and Communications
November 2, 2017

Liquid biopsies help reveal lung cancer mutations

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).

By VUMC News and Communications
May 4, 2017

Lovly elected to American Society for Clinical Investigation

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).

By VUMC News and Communications
April 24, 2017

Vanderbilt’s Christine Lovly elected to American Society for Clinical Investigation

By VUMC News and Communications
October 20, 2016

VICC trial putting lung cancer therapy to the test

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.
By VUMC News and Communications
June 22, 2016

Lovly tapped to brief Congress on cancer research

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science.
By Doug Campbell
May 26, 2016

Precision medicine already changing cancer treatment strategies

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.
By VUMC News and Communications
January 21, 2016

Lovly lands cancer research grant from V Foundation

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been awarded a V Scholar Grant from the V Foundation for Cancer Research.
By VUMC News and Communications
January 14, 2016

VICC helps expand cancer patient’s treatment options

Edward (Ned) Wikle recently celebrated the Christmas holidays with his wife and three young children, a celebration the Jackson, Mississippi-based endodontist, U.S. Navy veteran and cancer patient wasn’t sure he would have.
By VUMC News and Communications
March 12, 2015

Gene mutations may predict melanoma response to immunotherapies

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.
By VUMC News and Communications
1 2 3